Wall St Engine(@wallstengine):KENVUE $KVUE Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $4.0B (Est. $3.97B) 🟠; +3% YoY 🔹 Adj. EPS: $0.31 (Est. $0.32) 🔴; +7% YoY 🔹 Adjusted EBITDA: $941M (Est. $986M) 🔴 Segment Net Revenue: 🔹 Self Care: $1.6B; +2.2% YoY 🔹 Skin Health & Beauty: $1.1B; +5.1% YoY 🔹 Essential Health: $1.3B; +2.3% YoY Other Q2 Metrics: 🔹 Organic Sales Growth: 1.6% 🔹 Adjusted Operating Income Margin: 22.1%; -60 bps YoY 🔹 Net Income: $456M (Est. $600M) 🔴; +9% YoY 🔹 Free Cash Flow: $1.0B; +25% YoY 🔸 FDA Approval: Tylenol with Naproxen Comments: 🔸 “Our transformation is firmly on track.” 🔸 “completing our value-creating combination with Kimberly-Clark in the fourth quarter of this year.”

2026.08.06 10:48

KENVUE $KVUE Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $4.0B (Est. $3.97B) 🟠; +3% YoY 🔹 Adj. EPS: $0.31 (Est. $0.32) 🔴; +7% YoY 🔹 Adjusted EBITDA: $941M (Est. $986M) 🔴 Segment Net Revenue: 🔹 Self Care: $1.6B; +2.2% YoY 🔹 Skin Health & Beauty: $1.1B; +5.1% YoY 🔹 Essential Health: $1.3B; +2.3% YoY Other Q2 Metrics: 🔹 Organic Sales Growth: 1.6% 🔹 Adjusted Operating Income Margin: 22.1%; -60 bps YoY 🔹 Net Income: $456M (Est. $600M) 🔴; +9% YoY 🔹 Free Cash Flow: $1.0B; +25% YoY 🔸 FDA Approval: Tylenol with Naproxen Comments: 🔸 “Our transformation is firmly on track.” 🔸 “completing our value-creating combination with Kimberly-Clark in the fourth quarter of this year.”